AU2021405029A1 - Antibodies specific for structurally disordered sequences - Google Patents

Antibodies specific for structurally disordered sequences Download PDF

Info

Publication number
AU2021405029A1
AU2021405029A1 AU2021405029A AU2021405029A AU2021405029A1 AU 2021405029 A1 AU2021405029 A1 AU 2021405029A1 AU 2021405029 A AU2021405029 A AU 2021405029A AU 2021405029 A AU2021405029 A AU 2021405029A AU 2021405029 A1 AU2021405029 A1 AU 2021405029A1
Authority
AU
Australia
Prior art keywords
mab
seq
antigen
antibody
cdr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021405029A
Other languages
English (en)
Other versions
AU2021405029A9 (en
Inventor
Uli Binder
Lars Friedrich
Michaela Gebauer
Jonas SCHILZ
Martin Schlapschy
Arne Skerra
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Technische Universitaet Muenchen
XL Protein GmbH
Original Assignee
Technische Universitaet Muenchen
XL Protein GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Technische Universitaet Muenchen, XL Protein GmbH filed Critical Technische Universitaet Muenchen
Publication of AU2021405029A1 publication Critical patent/AU2021405029A1/en
Publication of AU2021405029A9 publication Critical patent/AU2021405029A9/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57581—Thymosin; Related peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2021405029A 2020-12-22 2021-12-22 Antibodies specific for structurally disordered sequences Pending AU2021405029A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20216744.1 2020-12-22
EP20216744 2020-12-22
PCT/EP2021/087365 WO2022136582A1 (en) 2020-12-22 2021-12-22 Antibodies specific for structurally disordered sequences

Publications (2)

Publication Number Publication Date
AU2021405029A1 true AU2021405029A1 (en) 2023-07-20
AU2021405029A9 AU2021405029A9 (en) 2025-03-13

Family

ID=73856935

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021405029A Pending AU2021405029A1 (en) 2020-12-22 2021-12-22 Antibodies specific for structurally disordered sequences

Country Status (9)

Country Link
US (1) US20240294632A1 (https=)
EP (1) EP4267628A1 (https=)
JP (1) JP2024501316A (https=)
KR (1) KR20230124637A (https=)
CN (1) CN117120476A (https=)
AU (1) AU2021405029A1 (https=)
CA (1) CA3200238A1 (https=)
IL (1) IL303816A (https=)
WO (1) WO2022136582A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118146384A (zh) * 2020-09-28 2024-06-07 安济盛生物医药有限公司 抗硬骨抑素构建体及其用途
EP4602053A2 (en) * 2022-10-14 2025-08-20 Aikium Inc. Protein scaffolds for disordered regions
WO2025088192A1 (en) * 2023-10-27 2025-05-01 Xl-Protein Gmbh Methods for the coupling of di(alkyl)amines to polypeptides
CN117683866B (zh) * 2024-01-22 2024-08-06 湛江中心人民医院 检测细胞中dna的方法
CN118290585B (zh) * 2024-06-04 2024-08-30 苏州为度生物技术有限公司天津分公司 一种抗人cd14工程抗体及应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2173890T1 (sl) 2007-06-21 2011-06-30 Univ Muenchen Tech Biološko aktivni proteini, ki imajo povečano in vivo in/ali in vitro stabilnost
US9221882B2 (en) 2010-05-21 2015-12-29 Technische Universitat Munchen Biosynthetic proline/alanine random coil polypeptides and their uses
WO2017109087A1 (en) 2015-12-22 2017-06-29 Xl-Protein Gmbh Nucleic acids encoding repetitive amino acid sequences rich in proline and alanine residues that have low repetitive nucleotide sequences
GB201600176D0 (en) * 2016-01-06 2016-02-17 Cambridge Entpr Ltd Method of identifying novel protein aggregation inhibitors based on chemical kinetics
CN110891612A (zh) 2017-06-21 2020-03-17 Xl-蛋白有限责任公司 蛋白质药物与p/a肽的缀合物

Also Published As

Publication number Publication date
WO2022136582A1 (en) 2022-06-30
JP2024501316A (ja) 2024-01-11
EP4267628A1 (en) 2023-11-01
AU2021405029A9 (en) 2025-03-13
KR20230124637A (ko) 2023-08-25
US20240294632A1 (en) 2024-09-05
CA3200238A1 (en) 2022-06-30
CN117120476A (zh) 2023-11-24
IL303816A (en) 2023-08-01

Similar Documents

Publication Publication Date Title
US20240294632A1 (en) Antibodies specific for structurally disordered sequences
US12275789B2 (en) Human antibodies binding to ROR2
EP3166973B1 (en) Immune-stimulating monoclonal antibodies against human interleukin-2
Hong et al. Site-specific C-terminal dinitrophenylation to reconstitute the antibody Fc functions for nanobodies
IL260689A (en) Ror1 antibody compositions and related methods
EP2180054A1 (en) Methods and compositions for prolonging elimination half-times of bioactive compounds
CN108884160A (zh) 抗ror1抗体
JP2013538566A (ja) 改良された抗血清アルブミン結合変異体
JP2023530663A (ja) 抗ＴＧＦβ抗体及びその治療的使用
AU2022252731A1 (en) Protein Binders For iRhom2
CN119137154A (zh) 抗叶酸受体α抗体及使用方法
Schilz et al. Molecular recognition of structurally disordered Pro/Ala-rich sequences (PAS) by antibodies involves an Ala residue at the hot spot of the epitope
TW201333034A (zh) 新穎抗人類ｃｔｇｆ抗體
CN113045659B (zh) 抗cd73人源化抗体
CN120077069A (zh) 趋化因子受体8（ccr8）抗体
CN116390945A (zh) 无细胞抗体工程化平台和针对SARS-CoV-2的中和抗体
EP1757311B1 (en) Methods and compositions for prolonging elimination half-times of bioactive compounds
RU2784586C2 (ru) Человеческие антитела, связывающиеся с ror2
JP2025508603A (ja) ネコ抗体ライブラリー
WO2021190437A1 (en) Antibodies against areg and its use
CN121758584A (zh) Pth复合物及其应用
KR20250039299A (ko) 항-il-6 도메인 항체
CN121609799A (zh) 一种抗pd-l1的纳米抗体、含其的双特异性重组蛋白及其应用
HK1099199A (en) Methods and compositions for prolonging elimination half-times of bioactive compounds

Legal Events

Date Code Title Description
SREP Specification republished